Treatment of Parkinson’s disease psychosis
Journal Title: Medicina Internacia Revuo - Year 2017, Vol 27, Issue 109
Abstract
Early in the course of Parkinson disease (PD), treatment usually goes well. However, after five to ten years, things start to change as treatment requires higher doses of medications and side effects become more problematic. One of the most difficult problems is the development of hallucinations or delusions. Throughout the 20th century, treatment options were unproven and unsatisfactory, but the past 20 years have brought important changes. Two medications that are well tolerated in PD have now proved efficacious in randomized, controlled trials, and others are in development. Here I summarize this history briefly and provide a general plan for treating the patient with PD complicated by psychotic symptoms.
Authors and Affiliations
Kevin Black
Keywords
Related Articles
- EP ID EP382070
- DOI -
- Views 72
- Downloads 0
Treatment planning of complicated endodontic cases with the use of CBCT
Including assessing dental morphology prior to endodontic treatment, locating tooth perforations, separated endodontic files, and resorptions. The aim of this paper was to present the usefulness of CBCT in endodontic tre...
Effect of zinc oxide nanoparticles on the expression of pro-inflammatory proteins in murine macrophages RAW 264.7 cells
Zinc is a microelement essential for the body. It has a great impact on the proper development and renewal of tissues, reproductive system, skin condition, or immune processes. Zinc is involved practically in all aspects...
Influence of αlpha-linolenic acid supplementation on murine macrophages RA W 264.7 activated with lipopolisaccharide
Chronic inflammation is characterized by excessive production of cytokines and eicosanoids and is associated with unsufficient resolution. Supplementation with n-3 fatty acids may result in a lower incidence of many infl...
Role of TCD emboli-monitoring in evaluation of efficacy of anticoagulant therapy in patients with nonvalvular atrial fibrillation
Background: Atrial fibrillation (AF) is a risk factor for stroke but, despite anticoagulation therapy, the risk of stroke is not completely eliminated. We evaluated the presence of microembolic signals (MES) by TCD embol...
Changes in pharmacokinetic properties of drugs in critically ill patients – Part I
The essential and the most difficult goal for the implementation of pharmacotherapy in critically ill patients is to achieve the desired pharmacological effect, while minimizing side effects of drugs. The desired pharmac...